Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3479847 | 1.00 | MAPK1 (0.40) | MAPK1F10HPGDTSHRLMNA | |
| SCHEMBL1024884 | 0.95 | F10 (0.43) | MAPK1F10HPGDTSHRLMNA | |
| SCHEMBL1024886 | 0.95 | F10 (0.43) | MAPK1F10HPGDTSHRLMNA | |
| SCHEMBL15731743 | 0.80 | F10 (0.48) | MAPK1F10HPGDTSHRLMNA | |
| SCHEMBL1004839 | 0.78 | F10 (0.44) | F10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3619642 | 0.78 | MEN1 (0.53) | HPGDTSHRLMNAKDM4ENPC1 | |
| SCHEMBL1022331 | 0.78 | F10 (0.71) | F10 | |
| SCHEMBL4458638 | 0.77 | MAPK1 (0.44) | MAPK1F10HPGDTSHRLMNA | |
| SCHEMBL3614270 | 0.77 | PRSS12 (0.44) | F10HPGDLMNAHTTALDH1A1 | |
| SCHEMBL3622276 | 0.77 | PRSS12 (0.42) | F10HPGDTSHRLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945634-B1 | PHENYLENEBISOXAZOLIDINE DERIVATIVES AND THEIR USE AS ANTICOAGULANTS | BAYER SCHERING PHARMA AG (DE) | 2011-01-19 | — | — | EP | disclosed |
| US-20100041646-A1 | Phenylene-Bis-Oxazolidine Derivatives and Their Use as Anticoagulants | BAYER HEALTHCARE AG (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041646-A1 | Phenylene-Bis-Oxazolidine Derivatives and Their Use as Anticoagulants | BAYER HEALTHCARE AG (DE) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041646-A1 | Phenylene-Bis-Oxazolidine Derivatives and Their Use as Anticoagulants | SELP, SERPINC1, F2 | MAPK1 1561/4885F10 346/4885HPGD 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.